Bioventus (BVS) Stock: Buy, Sell, or Hold?
BVS - Bioventus Inc. Class A Common Stock
$13.45
-0.18 (-1.32%)
▼
5d:
-0.52%
30d:
-1.61%
90d:
+28.34%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When BVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BVS trades at premium valuation expecting 8.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: BVS trades at premium valuation expecting 8.1% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.01
Based on 11.2% avg growth
INTRINSIC VALUE TODAY
$11.18
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BVS is currently trading at $13.45, which is considered fair relative to its 30-day fair value range of $13.18 to $14.05. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.6) compared to its historical average (11.6). At these levels, the market is pricing in 8.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BVS is in a strong uptrend. Immediate support is located at $12.34, while resistance sits at $14.15.
Market Sentiment: BVS scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.60 (+30.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BVS is in a strong uptrend. Immediate support is located at $12.34, while resistance sits at $14.15.
Market Sentiment: BVS scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.60 (+30.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.18 -
$14.05
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
59.6%
Protect Your Profits
Holding BVS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.9% below Wall St target ($17.60)
- NEUTRAL: PE elevated vs history but 8.1% growth expectation is conservative given 327% recent growth
Trading Range Analysis
30-Day Trading Range
$13.18 -
$14.05
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.31
(9.8%)
Support & Resistance Levels
Support Level
$12.34
Resistance Level
$14.15
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.62
Wall Street Target
$17.60
(+30.9%)
Revenue Growth (YoY)
3.8%
Earnings Growth (YoY)
327.3%
Profit Margin
9.4%
Valuation Premium vs History
+8.1% premium
PE vs Historical
14.6 vs 11.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.1%
(market-implied from PE analysis)
1-Year Target
$14.54
(+8%)
2-Year Target
$15.72
(+17%)
3-Year Target
$16.99
(+26%)
3-Yr Target (if PE normalizes)
(PE: 15→12)
PE COMPRESSION
$13.48
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 18.3%)
$31.03
(+131%)
Base:
(SPY PE: 14.6, Growth: 18.3%)
$22.24
(+65%)
Bear:
(PE: 11.6, Growth: 18.3%)
$17.65
(+31%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 17.93 | Current EPS (TTM): $0.76
Bull Case
$18.15
(+35%)
Analyst growth 21.1%, PE expands to 19.7
Base Case
$16.50
(+23%)
Market implied 21.1%, PE stable at 17.9
Bear Case
$9.27
(-31%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 7:37 AM ET
Data refreshes hourly during market hours. Next update: 8:37 AM
Data refreshes hourly during market hours. Next update: 8:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 57 HOLD |
Advanced BVS Option Strategies
Professional options setups generated by AI based on today's BVS price and gamma walls.
